immutep (asx:imm; nasdaq: immp) company update on start of 2021
Published 3 years ago • 125 plays • Length 7:43
Download video MP4
Download video MP3
Similar videos
-
7:43
immutep (asx:imm) company update on start of 2021
-
12:28
immutep (asx:imm, nasdaq:immp) ceo marc voigt provides an update on clinical trials
-
4:32
immutep (asx:imm) company update
-
6:25
immutep (asx:imm, nasdaq:immp) discusses a transformative year for lag-3 therapies
-
5:42
immutep (asx:imm, nasdaq:immp) receives fast track designation from fda - october 12, 2022
-
8:12
part 2 "marking candle 8am" (tkzamw)
-
5:19
cramer: this biotech stock could be worth over $100 billion on an fda approval
-
7:39
covid-19 (swing trading and technical analysis)
-
10:01
immutep limited (asx:imm, nasdaq:immp) encouraging results for immutep's cancer therapies
-
47:53
immutep (asx:imm, nasdaq:immp) tacti-003 results, june 2024
-
3:33
immutep (asx:imm) reports positive trial data
-
27:17
immutep limited (asx:imm, nasdaq:immp) - fireside chat with immutep limited
-
6:03
immutep (asx:imm, nasdaq:immp) reports positive discussions with the fda and strong survival data
-
7:09
immutep (asx:imm, nasdaq:immp) reports 71.4% response rate for lung cancer therapy, october 31, 2023
-
52:08
immutep (asx:imm, nasdaq:immp) global webcast presentation at sitc 2022
-
7:13
from the helm: immutep's (asx:imm, nasdaq:immp) executive director & ceo marc voigt
-
56:38
immutep (asx:imm, nasdaq:immp) webcast for tacti-002 data presented at asco 2022 - 10 jun 2022
-
6:42
immutep (asx:imm, nasdaq:immp) lag-3 validated in bristol myers squibb trial
-
6:59
immutep (asx:imm; nasdaq: immp) global leader in development of lag 3 gene immuno-therapies
-
4:44
immutep (asx:imm, nasdaq:immp) - innovative cancer therapies
-
31:08
immutep (asx:imm) 2023 agm - ceo presentation
-
15:49
immutep (asx:imm, nasdaq:immp) - sharecafe's "hidden gems" presentation, 17 february 2023
Clip.africa.com - Privacy-policy